Hubbry Logo
CXCR5CXCR5Main
Open search
CXCR5
Community hub
CXCR5
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
CXCR5
CXCR5
CXCR5
View on Wikipedia
from Wikipedia

CXCR5
Identifiers
AliasesCXCR5, BLR1, CD185, MDR15, C-X-C motif chemokine receptor 5, C-X-C chemokine receptor type 5
External IDsOMIM: 601613; MGI: 103567; HomoloGene: 1298; GeneCards: CXCR5; OMA:CXCR5 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

643

12145

Ensembl

ENSG00000160683

ENSMUSG00000047880

UniProt

P32302

Q04683

RefSeq (mRNA)

NM_032966
NM_001716

NM_007551

RefSeq (protein)

NP_001707
NP_116743

NP_031577

Location (UCSC)Chr 11: 118.88 – 118.9 MbChr 9: 44.42 – 44.47 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

C-X-C chemokine receptor type 5 (CXC-R5) also known as CD185 (cluster of differentiation 185) or Burkitt lymphoma receptor 1 (BLR1) is a G protein-coupled seven transmembrane receptor for chemokine CXCL13 (also known as BLC) and belongs to the CXC chemokine receptor family. It enables T cells to migrate to lymph node and the B cell zones. In humans, the CXC-R5 protein is encoded by the CXCR5 gene.[5]

Tissue distribution and function

[edit]

The BLR1 / CXCR5 gene is specifically expressed in Burkitt's lymphoma and lymphatic tissues, such as follicles in lymph nodes as well as in spleen. The gene plays an essential role in B cell migration.[6] Through CXCL13 secretions B cells are able to locate the lymph node.[6]

Additionally, some recent studies have suggested that CXCL13, through CXCR5, is capable of recruiting hematopoietic precursor cells (CD3− CD4+) which would cause the development of lymph nodes and Peyer's Patches.[7][8]

Other studies highlight the role of CXCR5 in T cells, as they are unable to access B cell follicles without CXCR5 expression.[9][10] This is a key step in the production of high affinity antibodies as B cells and T cells need to interact in order to activate the Ig class switch.[9]

CXCR5 has been shown to be expressed on both CD4[11] and CD8[12] T cells, though it is often regarded as the defining marker for T Follicular Helper (Tfh) cells.[13]

Role in cancer development

[edit]

Recently, it was shown that CXCR5 overexpression in breast cancer patients highly correlates with lymph node metastases,[14] and elevated CXCR5 expression may contribute to abnormal cell survival and migration in breast tumors that lack functional p53 protein.[15] Minor allele of SNP rs630923, located in the area of CXCR5 gene promoter and associated with the risk of multiple sclerosis, is responsible for appearance of MEF2C-binding site resulted in reduced CXCR5 gene promoter activity in B-cells during activation, that could lead to decreased autoimmune response [16]

While chemokines and chemokine receptors have been thought to be involved in cancer development and maintenance, recently CXCR5 has come under investigation for its role in metastatic progression of prostate cancer. A recent study has indicated that prostate cancer tissue as well as cell lines express higher non-basal levels of CXCR5.[17] Furthermore, the study found a correlation between the level of CXCR5 and Gleason score. CXCR5 location was additionally considered and higher Gleason scores correlated with nuclear CXCR5 while cytoplasmic and membrane CXCR5 correlated with benign and early prostate cancers.[17]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

CXCR5

View on Grokipedia
from Grokipedia
CXCR5, or C-X-C motif chemokine receptor 5, is a protein-coding gene located on chromosome 11q23.3 in humans that encodes a seven-transmembrane G protein-coupled receptor belonging to the CXC chemokine receptor family. This receptor is primarily expressed on mature B lymphocytes and follicular helper T (Tfh) cells, where it binds its specific ligand, CXCL13 (also known as B lymphocyte chemoattractant), to mediate the chemotaxis and homing of these immune cells to B cell follicles in secondary lymphoid organs such as lymph nodes, spleen, and Peyer's patches. Through this interaction, CXCR5 plays an essential role in the organization of lymphoid tissues, the development of germinal centers, and the coordination of humoral immune responses. Structurally, CXCR5 features two isoforms produced by : the longer isoform 1 with an extended and the shorter isoform 2, both functioning as multi-pass membrane proteins within the rhodopsin-like GPCR superfamily. Expression of CXCR5 is highest in lymphoid tissues, including lymph nodes (RPKM 22.1) and (RPKM 17.8), underscoring its specialization in adaptive immunity. In Tfh cells, CXCR5 expression is induced during antigen priming and is indispensable for their entry into follicles, enabling interactions that drive activation, affinity maturation, and production. Beyond its physiological functions, the CXCR5/CXCL13 axis is implicated in pathological conditions, including autoimmune diseases where it promotes ectopic lymphoid neogenesis and chronic inflammation, as well as in cancers such as B cell lymphomas and solid tumors, where it facilitates immune cell infiltration into the tumor microenvironment. In infections, CXCR5 supports protective immune responses but can also contribute to immunopathology in chronic settings like Helicobacter pylori-induced gastritis. These roles position CXCR5 as a potential therapeutic target for modulating immune responses in disease.

Discovery and Molecular Basics

Discovery

The chemokine receptor CXCR5, initially designated as Burkitt's lymphoma receptor 1 (BLR1), was first cloned in 1992 from the human Burkitt's lymphoma cell line Namalwa, revealing it as a novel seven-transmembrane with homology to other s. Dobner et al. identified its cDNA through differential screening of a library from these cells, noting high expression in Burkitt's lymphoma and mature B lymphocytes, which hinted at a role in lymphoid . This seminal work established CXCR5 as an within the CXC receptor family. Subsequent studies in 1993 extended the characterization to the murine ortholog, with et al. demonstrating its expression in developing s and neuronal tissues, linking BLR1 to differentiation during murine . An independent human cloning effort, reported in 1995 by Barella et al., isolated the same receptor from activated monocytes and termed it monocyte-derived receptor 15 (MDR15), confirming sequence identity to BLR1 and further solidifying its identity across cell types. The human was mapped to 11q23.3 through and linkage analysis in subsequent genetic studies. Early functional investigations in the mid-1990s focused on its potential in immune cell migration, with expression patterns suggesting involvement in B cell homing. By 1998, Legler et al. identified the specific ligand for CXCR5 as B cell-attracting chemokine 1 (BCA-1, later renamed CXCL13), a CXC chemokine produced in lymphoid tissues that selectively induces chemotaxis of B lymphocytes but not T cells or monocytes via this receptor. This ligand-receptor pairing provided critical evidence for CXCR5's role in directing B cell trafficking to follicles in secondary lymphoid organs, marking a key milestone in its characterization. The receptor was officially designated CXCR5 in 1998 as part of the systematic chemokine receptor nomenclature.

Gene and Nomenclature

The gene encoding the C-X-C motif 5 is officially designated CXCR5 by the (HGNC ID: HGNC:1060), with the full name C-X-C motif 5, and is assigned Gene ID 643. Previously known as BLR1 (B-lymphocyte receptor 1) or MDR15 (monocyte-derived receptor 15), the gene was initially cloned in 1992 from a Burkitt's lymphoma cell line as an orphan with expression restricted to B lymphocytes. The CXCR5 gene is located on the long arm of human at cytogenetic band 11q23.3, with genomic coordinates spanning from 118,883,892 to 118,897,787 (GRCh38 assembly), encompassing approximately 14 kb of genomic DNA. It consists of two s, with the coding sequence primarily in the second , typical of many genes. Alternative nomenclature includes CD185, reflecting its identification as a marker on immune cells. The CXCR5 sequence is highly conserved across mammalian , with orthologs identified in (Cxcr5, located on ) and other vertebrates, underscoring its evolutionary preservation in lymphoid organization and immune cell trafficking. For instance, the ortholog shares substantial similarity with the protein, facilitating cross-species functional studies.

Protein Structure and Ligand Interaction

Receptor Structure

CXCR5 is a class A seven-transmembrane domain (GPCR) encoded by the human on 11q23.3, comprising 372 with a predicted molecular weight of approximately 41.5 kDa. The receptor adopts a typical GPCR topology, featuring an extracellular N-terminal domain that facilitates recognition and an intracellular C-terminal tail that mediates interactions with G proteins and other signaling effectors. This architecture positions CXCR5 within the subfamily, characterized by a bundle of seven α-helical transmembrane segments connected by three intracellular and three extracellular loops. Key structural motifs conserved among class A GPCRs are present in CXCR5, including the DRY box (Asp-Arg-Tyr) at the intracellular end of transmembrane helix 3 (TM3), which plays a critical role in coupling and receptor activation. Additionally, conserved residues, notably one in TM3 (Cys^{3.25}) and another in the second extracellular loop (ECL2, Cys^{45.50}), form a bridge essential for maintaining the structural integrity of the extracellular domain and ligand-binding pocket. As of 2025, no experimentally determined crystal or cryo-EM structure of CXCR5 exists, limiting direct biophysical insights; however, homology models based on closely related receptors, such as CXCR4 (PDB ID: 3ODU), reveal a ligand-binding site in the transmembrane helical bundle and highlight similarities in the activation mechanism involving outward tilting of TM6. These models underscore the conserved helical arrangement and motif positioning that enable CXCR5's function in chemokine signaling.

Ligand Binding

The primary ligand for CXCR5 is , also known as B lymphocyte chemoattractant (BLC) or B cell-activating factor-1 (BCA-1), a homeostatic CXC predominantly produced by stromal cells within secondary lymphoid organs such as lymph nodes and . This ligand guides the migration and positioning of CXCR5-expressing cells, including B and , to lymphoid follicles. CXCL13 binds to CXCR5 with high affinity, typically exhibiting a (Kd) in the range of 1-10 nM, as determined through radioligand binding assays and functional migration studies. The interaction primarily involves the flexible N-terminal domain of CXCL13, which inserts into the receptor's orthosteric pocket, and the extracellular loops (ECLs) of CXCR5, particularly ECL2 and ECL3, which contribute to ligand recognition and specificity. CXCR5 functions as the sole receptor for , demonstrating remarkable specificity with negligible binding to other , a property confirmed by competitive binding assays showing exclusive by CXCL13 among CXC family members. Binding dynamics have been elucidated through experimental approaches, including saturation binding assays and studies from the early 2000s onward. For example, mutagenesis targeting charged residues in CXCR5's extracellular loops and polar clusters has revealed their role in stabilizing the CXCL13-CXCR5 complex, while alterations to CXCL13's N-terminal residues, such as substitutions at Val1 and Leu2, modulate binding affinity and downstream without abolishing recognition.

Expression Patterns

Cellular Expression

CXCR5 is primarily expressed on mature s, enabling their homing to B cell follicles in secondary lymphoid organs through responsiveness to its ligand CXCL13. This expression is characteristic of recirculating follicular B cells, which constitute a significant portion of peripheral B lymphocytes and play a key role in maintaining lymphoid architecture during . Virtually all mature B cells display CXCR5 on their surface, distinguishing them from precursors and supporting their positioning within germinal centers for antigen-driven responses. High levels of CXCR5 are also observed on T follicular helper (Tfh) cells, a specialized + T cell subset within secondary lymphoid organs that provides essential help to s for antibody production and class switching. CXCR5 expression defines Tfh cells and their regulatory counterparts, follicular regulatory T cells (Tfr), allowing these populations to migrate into follicles and modulate reactions. Additionally, subsets of + T cells in lymphoid tissues express CXCR5, contributing to follicular residency and immune regulation under homeostatic conditions. During T cell activation, naive + T cells transiently upregulate CXCR5 in response to antigenic stimulation, facilitating their differentiation into Tfh precursors and initial migration toward follicular regions. This expression is dynamic and diminishes if cells do not receive appropriate costimulatory signals, ensuring selective commitment to the Tfh lineage. Certain subsets, particularly those involved in within lymphoid tissues, also express CXCR5, allowing them to respond to and position themselves at the T-B cell border to initiate adaptive responses. In development, CXCR5 expression is developmentally regulated, with upregulation occurring during the transition from immature stages to mature recirculating s in the . This process is driven by B cell-activating factor (BAFF), which directly induces CXCR5 on IgM+ precursors in the , promoting their migration to splenic follicles and integration into the peripheral pool. In the absence of BAFF, CXCR5 levels on these cells are markedly reduced, underscoring its role in maturation and compartmentalization.

Tissue Distribution

CXCR5 exhibits predominant expression in secondary lymphoid tissues, including lymph nodes, spleen, and Peyer's patches, where it is essential for lymphoid organization. According to data from the GTEx (as summarized in NCBI , latest release), CXCR5 shows the highest median expression levels in lymph nodes (22.1 RPKM) and (17.8 RPKM), with notable enrichment also in tissues containing lymphoid structures such as the terminal . Constitutive expression of CXCR5 is low in peripheral blood and bone marrow, with minimal detection on hematopoietic precursors or plasma cells in the latter. In non-lymphoid tissues, CXCR5 expression remains negligible under homeostatic conditions but can be induced in inflamed environments, such as through transient upregulation on activated immune cells. Within secondary lymphoid organs, CXCR5 protein distribution is highly compartmentalized, as revealed by studies, with expression largely confined to follicles and germinal centers. This pattern aligns with its localization primarily on mature and in these microenvironments.

Signaling Mechanisms

Downstream Pathways

Upon ligand binding, CXCR5, a G protein-coupled receptor, primarily couples to the heterotrimeric G protein Gαi, leading to the dissociation of Gαi from the βγ subunits and subsequent activation of downstream effectors. This Gαi-mediated signaling inhibits adenylate cyclase activity, resulting in decreased intracellular cyclic AMP (cAMP) levels, which facilitates chemotaxis and directed migration of B cells and T follicular helper cells toward lymphoid follicles. In immune cells, this reduction in cAMP promotes cell polarization and motility essential for adaptive immune responses. The βγ subunits released from Gαi further activate the phosphoinositide 3-kinase (PI3K) pathway, recruiting PI3K to the plasma membrane and generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which in turn phosphorylates and activates Akt (also known as protein kinase B). This PI3K-Akt signaling cascade enhances cell survival by inhibiting pro-apoptotic proteins such as Bad and FoxO transcription factors, while also promoting migration through regulation of focal adhesion dynamics in CXCR5-expressing cells like B lymphocytes and certain cancer cells. In pathological contexts, such as prostate cancer, sustained PI3K-Akt activation drives invasion and metastasis. CXCR5 signaling also engages the (MAPK)/extracellular signal-regulated kinase (ERK) pathway, where activation leads to sequential of Raf, MEK, and ERK kinases, culminating in ERK nuclear translocation. This pathway regulates for proliferation and differentiation, particularly in T cells, supporting their role in formation. Additionally, evidence suggests involvement of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, with of observed in response to CXCR5 activation, contributing to immunosuppressive effects like recruitment in tumor microenvironments. For , CXCR5 specifically activates Rho family , including Rac1 and Cdc42, downstream of Gαi and PI3K signaling. These orchestrate rearrangement by promoting lamellipodia and formation, respectively, enabling efficient cell movement toward gradients in lymphoid tissues. In B cells, Rac1 activation is critical for directional migration, with disruptions leading to impaired follicle homing.

Regulatory Mechanisms

Upon activation by its ligand , CXCR5 undergoes rapid desensitization through of serine and residues in its carboxyl-terminal tail by kinases (GRKs), particularly involving distal and medial phospho-site clusters (e.g., T367, S368, T370, T371 and S358, S359, S361, S363). This recruits β-arrestins, which sterically hinder further coupling, thereby terminating signaling and preventing sustained activation. Studies using bioluminescence resonance energy transfer (BRET) assays in HEK293 cells demonstrated dose-dependent β-arrestin recruitment to phosphorylated CXCR5, with mutations in these clusters abolishing recruitment and leading to prolonged cAMP inhibition responses in β-arrestin-deficient cells. Internalization of activated CXCR5 occurs primarily through clathrin-coated pits in a β-arrestin-independent manner, as evidenced by enzyme-linked immunosorbent assay () measurements showing 70-80% receptor internalization within 30-60 minutes upon stimulation, unaffected by β-arrestin knockout. Following , internalized CXCR5 can either recycle back to the plasma membrane via Rab GTPase-mediated pathways or undergo lysosomal degradation, depending on the duration of ligand exposure and ubiquitination status; di-leucine motifs and lysine residues in the tail (e.g., L336, L337, K328, K339) influence sorting but are not essential for trafficking. This dynamic process allows for receptor resensitization or downregulation to fine-tune responsiveness during migration. The expression of CXCR5 on B cells is subject to by factors such as Foxo1, which contributes to the programs governing B cell identity and positioning, with altered Foxo1 activity leading to changes in profiles including Cxcr5 in models. Additionally, CXCR5 engages in with other receptors like , where activation of CXCR5 by triggers (PKC)-dependent heterologous desensitization, internalization, ubiquitination, and lysosomal degradation of via GRK6 and AIP4 E3 ligase, reducing CXCR4 surface levels by approximately 60% and modulating B cell homing from retention to follicular entry. This reciprocal regulation ensures coordinated B cell trafficking in lymphoid tissues.

Physiological Functions

Role in Lymphoid Organogenesis

CXCR5 plays an essential role in the development and organization of secondary lymphoid organs by directing the migration of B cells to form follicles during both prenatal and postnatal stages. In CXCR5-deficient mice, the formation of inguinal lymph nodes is completely absent, and Peyer's patches are severely reduced or disorganized, demonstrating its necessity for proper lymphoid organogenesis. This receptor facilitates the clustering of B cells in response to CXCL13 gradients produced by stromal cells, establishing the foundational architecture of B cell compartments in lymph nodes and other lymphoid tissues. The - axis is particularly critical for recruiting CXCR5-expressing s and follicular helper T (Tfh) cells to organize the white pulp in the . , secreted by and stromal cells within developing follicles, creates a loop that amplifies accumulation and Tfh cell entry, thereby segregating B cell zones from T cell areas and enabling structured lymphoid microenvironments. This process ensures the required for efficient immune cell interactions in the spleen's white pulp during organ development. Studies in CXCR5-knockout mice reveal profoundly disrupted splenic architecture, with B cells failing to form distinct follicles and instead dispersing diffusely, leading to the formation of disorganized germinal centers in the T cell zones even under antigenic stimulation. These mice exhibit a lack of B cell follicle maturation in the and nodes, underscoring CXCR5's indispensable function in maintaining lymphoid tissue integrity. Although small clusters of B cells may form aberrantly in T cell zones, the overall impairment highlights the receptor's role in establishing functional lymphoid structures. Beyond primary , the CXCR13-CXCR5 axis contributes to the formation of tertiary lymphoid structures (TLS) in sites of chronic inflammation, where of recruits B cells and Tfh cells to generate follicle-like aggregates. In models of persistent inflammation, CXCR5 signaling drives the organization of these inducible structures, mimicking secondary lymphoid organs and supporting localized immune responses. This mechanism links ongoing inflammatory cues to the de novo assembly of lymphoid tissue in non-lymphoid sites.

Role in Adaptive Immunity

CXCR5 plays a central role in adaptive immunity by directing the migration of s and follicular helper T (Tfh) cells into germinal centers (GCs) within secondary lymphoid organs, where affinity maturation of antibodies occurs. Through its interaction with the , CXCR5 enables these cells to respond to concentration gradients, facilitating their entry and positioning within B cell follicles. This chemotactic guidance is essential for the selection and proliferation of high-affinity clones during the humoral . The receptor further promotes critical interactions between Tfh and s in the GCs, driven by gradients that maintain spatial organization in follicles and light zones. These interactions allow Tfh cells to provide co-stimulatory signals, such as CD40L and IL-21, which support survival, proliferation, and differentiation into plasma cells. This process is vital for generating robust responses against pathogens. CXCR5 contributes to class-switch recombination (CSR) and the formation of s by sustaining Tfh-B cell collaborations in the GC environment. During CSR, activated s undergo genetic rearrangements to produce isotype-switched antibodies, such as IgG or IgA, while s emerge for long-term immunity; disruptions in CXCR5 signaling impair these outcomes. Evidence from vaccination studies underscores CXCR5's importance, as its deficiency or blockade leads to impaired humoral responses. For instance, in models of and vaccination, CXCR5-deficient circulating Tfh cells result in reduced and titers, highlighting the receptor's necessity for effective vaccine-induced immunity.

Pathological Implications

Involvement in Cancer

CXCR5 is frequently overexpressed in various B cell malignancies, including and (CLL). In , high CXCR5 expression is observed on neoplastic B cells, contributing to their localization within lymphoid follicles and association with advanced disease stages. Similarly, in CLL, malignant B cells exhibit significantly elevated surface CXCR5 levels compared to normal CD5- B cells, with expression comparable to normal CD5+ B cells, enabling enhanced responsiveness to its ligand . This overexpression facilitates the homing of tumor cells to lymphoid niches, where CXCL13 gradients guide their migration and survival. The CXCR5-CXCL13 axis plays a critical role in tumor and in B cell lymphomas by promoting toward lymphoid structures. In preclinical models of , CXCR5 engagement with drives the directional movement of lymphoma cells into B cell follicles, enhancing their proliferation and resistance to within protective microenvironments. This migratory behavior not only supports tumor dissemination but also perpetuates a cycle of lymphoid organ colonization. CXCR5 contributes to an immunosuppressive tumor microenvironment in B cell malignancies through the recruitment of T follicular helper (Tfh) cells, which foster tumor-supportive interactions. In nodal B cell non-Hodgkin lymphomas, CXCR5-expressing Tfh cells are enriched in the tumor stroma, where they provide help to malignant B cells via CD40L and cytokines like IL-21, suppressing effective antitumor immunity and promoting B cell proliferation. This recruitment is mediated by CXCL13 produced by lymphoma-associated stromal cells, leading to Tfh accumulation that correlates with poorer prognosis in follicular lymphoma patients. In solid tumors, the CXCR5/CXCL13 axis exhibits dual roles, promoting immune cell infiltration into the tumor microenvironment to form tertiary lymphoid structures (TLS) that can enhance antitumor immunity, particularly in response to immune checkpoint inhibitors (as of 2024), while also facilitating metastasis and immunosuppression in certain contexts such as renal cell carcinoma and non-small cell lung cancer. Therapeutic targeting of CXCR5 has shown promise in preclinical models of lymphoma, particularly through antagonists and engineered therapies that disrupt tumor cell and Tfh dynamics. Post-2015 studies demonstrate that anti-CXCR5 chimeric antigen receptor (CAR) T cells effectively eliminate both lymphoma B cells and associated Tfh cells in murine models of nodal B cell non-Hodgkin lymphoma, reducing tumor burden and metastasis without significant off-target effects on normal B cells. Additionally, CXCR5-targeted antibody-drug conjugates exhibit potent antitumor activity in diffuse large B cell lymphoma and follicular lymphoma xenografts, outperforming non-targeted controls by inducing apoptosis in CXCR5-high tumor cells. Recent insights highlight CXCR5/CXCL13 as a biomarker for immunotherapy efficacy and a contributor to immune-related adverse events (as of 2024). These approaches highlight CXCR5 as a viable target for improving outcomes in B cell malignancies by simultaneously addressing tumor migration and immune evasion.

Involvement in Autoimmune and Inflammatory Diseases

CXCR5 plays a critical role in the of autoimmune diseases by facilitating the migration and accumulation of T follicular helper (Tfh) cells and B cells in inflamed tissues, leading to dysregulated and production. In conditions such as (RA) and Sjögren's syndrome, aberrant CXCR5 signaling promotes the formation of ectopic lymphoid structures (ELS), which sustain chronic inflammation and self-reactive immune responses. In , CXCR5 is upregulated in synovial tissues, where it drives the infiltration of CXCR5-expressing T and s into the synovium, contributing to the development of ELS that resemble germinal centers. These structures support local production and perpetuate joint inflammation, with elevated (the primary ligand for CXCR5) detected in areas of accumulation within the synovium. This upregulation correlates with disease severity, as CXCR5-mediated colocalization of Tfh and s in secondary lymphoid organs is essential for initiating pathogenic responses in models. Similarly, in primary Sjögren's syndrome, CXCR5 is associated with enhanced Tfh cell activity, which promotes B cell hyperactivity and the production of autoantibodies such as anti-SSA/Ro and anti-SSB/La. Circulating CXCR5+ CD4+ T cells, indicative of Tfh-like populations, are increased in patients and correlate with salivary gland infiltration and autoantibody titers, exacerbating glandular inflammation and systemic autoimmunity. In chronic inflammatory conditions such as , CXCR5 supports the development of ectopic lymphoid tissues in the , contributing to sustained and potential progression to . Genome-wide association studies (GWAS) from the 2010s have identified single nucleotide polymorphisms (SNPs) near the CXCR5 gene as risk factors for (MS), linking genetic variations in CXCR5 to altered expansion and increased susceptibility to . Specifically, variants at the 11q23.3 locus, including those influencing CXCR5 expression, are associated with MS risk and may modulate immune cell trafficking across the blood-brain barrier. Experimental evidence from animal models underscores CXCR5's pathogenic role, as CXCR5 mice exhibit reduced disease severity in collagen-induced , a model of , due to impaired Tfh cell formation and diminished responses. This resistance highlights the axis's necessity for autoimmune progression, with global or T cell-specific CXCR5 deficiency preventing and production.

References

  1. https://www.ncbi.nlm.nih.gov/gene/643
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4459225/
  3. https://rupress.org/jem/article/197/9/1199/39776/Cooperating-Mechanisms-of-CXCR5-and-CCR7-in
  4. https://ashpublications.org/blood/article/106/6/1924/21598/Balanced-expression-of-CXCR5-and-CCR7-on
  5. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.850998/full
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8774093/
  7. https://link.springer.com/article/10.1007/s00109-010-0658-6
  8. https://doi.org/10.1002/eji.1830231023
  9. https://www.omim.org/entry/601613
  10. https://pubmed.ncbi.nlm.nih.gov/9463416/
  11. https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1060
  12. https://www.uniprot.org/uniprotkb/P32302/entry
  13. https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01309
  14. https://pubmed.ncbi.nlm.nih.gov/19251935/
  15. https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-93
  16. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.703088/full
  17. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/cxcr5-receptor
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC5666081/
  19. https://www.mdpi.com/2072-6694/14/2/294
  20. https://ashpublications.org/blood/article/110/9/3316/23965/Overexpression-of-the-CXCR5-chemokine-receptor-and
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7543660/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC9454489/
  23. https://rupress.org/jem/article/192/11/1553/20187/Cxc-Chemokine-Receptor-5-Expression-Defines
  24. https://onlinelibrary.wiley.com/doi/full/10.1002/eji.200636136
  25. https://onlinelibrary.wiley.com/doi/pdf/10.1002/1521-4141%2528200010%252930%253A10%253C2808%253A%253AAID-IMMU2808%253E3.0.CO%253B2-K
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10011739/
  27. https://www.proteinatlas.org/ENSG00000160683-CXCR5/tissue
  28. https://www.nature.com/articles/s41467-020-20488-3
  29. https://reactome.org/content/detail/R-HSA-444505
  30. https://doi.org/10.3389/fendo.2019.00471
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC9913146/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2873439/
  33. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00296/full
  34. https://doi.org/10.1016/j.canlet.2024.217278
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC4898593/
  36. https://rupress.org/jem/article/207/4/837/40692/A-novel-Rac-dependent-checkpoint-in-B-cell
  37. https://doi.org/10.1124/molpharm.124.000942
  38. https://doi.org/10.1016/j.cytogfr.2005.05.008
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC5379976/
  40. https://doi.org/10.1074/jbc.RA118.005991
  41. https://doi.org/10.1002/1521-4141(200002)30:2%3C560::AID-IMMU560%3E3.0.CO;2-T
  42. https://doi.org/10.1038/nri3700
  43. https://doi.org/10.1038/ni.3054
  44. https://doi.org/10.1073/pnas.1520112113
  45. https://doi.org/10.1016/j.immuni.2013.09.007
  46. https://doi.org/10.1126/scitranslmed.3005191
  47. https://aacrjournals.org/cancerres/article/83/7_Supplement/6294/721035/Abstract-6294-CXCR5-is-a-very-promising-drug
  48. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00471/full
  49. https://www.cell.com/trends/cancer/fulltext/S2405-8033(22)00270-9
  50. https://www.sciencedirect.com/science/article/pii/S0304383524006736
  51. https://pubmed.ncbi.nlm.nih.gov/24729415/
  52. https://www.nature.com/articles/s41598-017-08935-6
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC7944988/
  54. https://academic.oup.com/brain/article/136/6/1778/621784
Add your contribution
Related Hubs
User Avatar
No comments yet.